Immune cells that create and sustain chronic inflammatory bowel disease identified

June 26, 2018 by Jeff Hansen, University of Alabama at Birmingham
Laurie Harrington. Credit: UAB

In preclinical experiments, Laurie Harrington, Ph.D., and colleagues at the University of Alabama at Birmingham have discovered a subset of immune cells that create and sustain chronic inflammatory bowel disease. These cells could become potential therapeutic targets to ameliorate or cure Crohn's disease and ulcerative colitis.

Furthermore, if this subset of CD4 T plays a similar role in other autoimmune diseases, such as Type 1 diabetes or rheumatoid arthritis, they could also be targets for therapy.

"We think these cells could be in a number of auto-inflammatory diseases," said Harrington, an associate professor in the UAB Department of Cell, Developmental and Integrative Biology. "Our hope is, if we could treat these cells, it could be curative."

Inflammatory bowel , or IBD, has two forms: Crohn's disease, which can affect any part of the gastrointestinal tract but most often occurs in the lower small intestine; and ulcerative colitis, found in the large intestine and rectum. In both, prolonged inflammation damages the GI tract, accompanied by symptoms that include persistent diarrhea and abdominal pain.

IBD is an autoimmune disease caused by a dysfunctional immune response, yet the mechanisms of how the cause chronic inflammation and pathology are unknown. In IBD, the cytokine interferon-gamma is abundantly produced by a type of immune cells called CD4 T cells, yet there is conflicting information about the role of interferon-gamma in the disease.

The immune system in mammals functions via an exquisite series of interactions among a large cast of different immune cells. The goal is to trigger a response that will identify and eliminate infecting bacteria or viruses, and then turn off that response when the infection is gone. At the same time, the immune response is not supposed to attack a person's own cells, a harmful attack that is called autoimmunity.

This tightly controlled immunity starts with blood-line stem cells in the bone marrow that have the capacity to differentiate into a large number of different immune cells. The stem cells themselves can divide indefinitely. The stem cells produce intermediate cells known as . Progenitor cells can divide for a while, but not indefinitely, and they have the ability to further differentiate into one or several types of fully differentiated immune cells.

As an example, effector CD4 T cells are progenitors that can differentiate into various types of T-helper cells that are found in IBD.

In a mouse model of colitis, Harrington, first author Boyoung Shin and colleagues found that effector CD4 T cells exist in a spectrum of differentiation states, and the pathogenic potential of the cells was directly linked to the differentiation status.

They were able to separate the CD4 T cells into two groups: interferon-gamma-producing CD4 T cells and CD4 T cells that did not produce interferon-gamma. The interferon-gamma-positive CD4 T cells were not able to confer colitis when transferred to healthy mice, and those cells were not required to sustain disease.

In contrast, it was the interferon-gamma-negative CD4 T cells that were pathogenic. Those cells were capable of eliciting and maintaining intestinal inflammation. That group showed a stem cell-like transcriptional signature, which supports the capacity to self-renew and resist the programmed cell death, called apoptosis. They also continually seeded terminally differentiated, interferon-gamma-producing cells in the inflamed intestine.

The researchers also identified a glycosyltransferase enzyme in the interferon-gamma-negative CD4 T cells that positively regulated a transcription factor involved in stemness.

Similar to the Harrington study, a different group of researchers recently found there is a distinct subset of CD8 T cells that sustains the control of chronic viral infections, and this unique cell population is distinguished by its stem-like qualities.

Besides Harrington and Shin, co-authors of the study, "Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation," published in the Journal of Experimental Medicine, are Robert L. Kress and Susan L. Bellis, UAB Department of Cell, Developmental and Integrative Biology; and Philip A. Kramer and Victor M. Darley‑Usmar, UAB Department of Pathology.

Explore further: Some blood stem cells are better than others

More information: Boyoung Shin et al, Effector CD4 T cells with progenitor potential mediate chronic intestinal inflammation, The Journal of Experimental Medicine (2018). DOI: 10.1084/jem.20172335

Related Stories

Some blood stem cells are better than others

May 30, 2018
In your body, blood stem cells produce approximately 10 billion new white blood cells, which are also known as immune cells, each and every day. Even more remarkably, if some of these blood stem cells fail to do their part, ...

Igniting the rheumatoid arthritis flame through a cellular cascade

May 30, 2018
Chronic inflammatory disorders, including autoimmune diseases such as rheumatoid arthritis, involve the action of various inflammatory molecules (cytokines) produced by cells of the immune system. One such cytokine, IL-17, ...

Oxysterols guide gut immune cells and are involved in inflammatory bowel disease

January 16, 2018
Researchers at Karolinska Institutet in Sweden report that cholesterol metabolites cause specific immune cells in the large intestine to move, which lies behind the formation of the immune system's important lymphoid tissue ...

Smoking may cause inflammatory bowel disease

October 31, 2017
A new study shows a direct effect of cigarette smoke on intestinal inflammation for the first time. Researchers in South Korea report that exposing mice to cigarette smoke results in colitis, an inflammation of the colon ...

Researchers find new clue in lupus autoantibody production

April 12, 2016
A signaling molecule called interferon gamma could hold the key to understanding how harmful autoantibodies form in lupus patients. The finding could lead to new treatments for the chronic autoimmune disease, said researchers ...

Cytokine controls immune cells that trigger inflammatory bowel disease, study finds

April 18, 2017
A certain cytokine, or small protein that helps cells communicate during immune responses, can control whether immune cells promote or suppress inflammatory bowel disease, a finding that could lead to new treatments, according ...

Recommended for you

Fatty acids can slow down an overheated immune system

September 21, 2018
Sometimes, the immune system mistakenly attacks the body's healthy tissue by responding to infections that do not exist. This causes chronic inflammation and leads to diseases including lupus (SLE), and this is what happens ...

Study reveals a promising alternative to corticosteroids in acute renal failure treatment

September 21, 2018
A protein produced by the human body appears to be a promising new drug candidate to treat conditions that lead to acute renal failure. This is shown by a study conducted at São Paulo State University (UNESP) in São José ...

Rethinking an inflammatory receptor's obesity connection

September 12, 2018
Toll-like receptor 4 (TLR4) is a protein that plays a vital role in the body's immune response by sensing the presence of infection. It has long been thought to also sense particular types of fats, which suggested a mechanism ...

Excessive airway nerves tied to more severe asthma symptoms, study finds

September 5, 2018
A new study implicates remodeling of nerves in the airways as a key contributor to heightened sensitivity and airway constriction in patients with asthma.

Genetics and pollution drive severity of asthma symptoms

August 31, 2018
Asthma patients, with a specific genetic profile, exhibit more intense symptoms following exposure to traffic pollution, according to researchers at the National Institutes of Health and collaborators. The study appeared ...

Clarifying the role of a protein released by immune 'dendritic' cells could yield better treatments

August 30, 2018
Inflammatory bowel disease (IBD), which afflicts millions of people worldwide, arises when the immune system mounts an overly aggressive response against microorganisms, dietary substances, or cells of the gut. A*STAR researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.